# A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

> **NCT05656040** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 14 (actual)

## Conditions studied

- End-Stage Renal Disease
- End-Stage Kidney Disease
- Kidney Failure, Chronic

## Interventions

- **BIOLOGICAL:** MK-2060
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05656040
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-08
- **Primary completion:** 2024-08-12
- **Final completion:** 2024-08-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05656040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05656040, "A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05656040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*